End	O
points	O

All	B-OtherOutcome
AEs	I-OtherOutcome
,	I-OtherOutcome
serious	I-OtherOutcome
and	I-OtherOutcome
non	I-OtherOutcome
-	I-OtherOutcome
serious	I-OtherOutcome
,	O
were	O
to	O
be	O
reported	O
.	O

Immediately	O
reportable	O
serious	O
adverse	O
events	O
included	O
adverse	O
events	O
that	O
resulted	O
in	O
death	O
and	O
new	O
life	O
-	O
threatening	O
events	O
.	O

The	O
primary	O
outcome	O
was	O
defined	O
as	O
relative	B-PrimaryOutcome
change	I-PrimaryOutcome
(	I-PrimaryOutcome
%	I-PrimaryOutcome
)	I-PrimaryOutcome
from	I-PrimaryOutcome
baseline	I-PrimaryOutcome
(	I-PrimaryOutcome
day	I-PrimaryOutcome
1	I-PrimaryOutcome
prior	I-PrimaryOutcome
to	I-PrimaryOutcome
study	I-PrimaryOutcome
drug	I-PrimaryOutcome
administration	I-PrimaryOutcome
at	I-PrimaryOutcome
Â±	I-PrimaryOutcome
1h	I-PrimaryOutcome
of	I-PrimaryOutcome
randomization	I-PrimaryOutcome
)	I-PrimaryOutcome
in	I-PrimaryOutcome
PaO2	I-PrimaryOutcome
/	I-PrimaryOutcome
FiO2	I-PrimaryOutcome
ratio	I-PrimaryOutcome
in	I-PrimaryOutcome
supine	I-PrimaryOutcome
position	I-PrimaryOutcome
at	B-TimeFrame
day	I-TimeFrame
five	I-TimeFrame
.	O

During	O
the	O
study	O
it	O
became	O
clear	O
that	O
several	O
patients	O
in	O
prone	O
position	O
could	O
not	O
be	O
assessed	O
regularly	O
in	O
supine	O
position	O
because	O
of	O
severe	O
hypoxemia	O
.	O

It	O
was	O
therefore	O
decided	O
to	O
focus	O
on	O
all	O

PaO2	O
/	O
FiO2	O
ratioassessments	O
(	O
irrespective	O
of	O
position	O
)	O
and	O
perform	O
an	O
analysis	O
of	O
supine	O
position	O
values	O
for	O
sensitivity	O
.	O

Various	O
additional	O
secondary	O
and	O
other	O
outcomes	O
were	O
pre	O
-	O
defined	O
in	O
line	O
with	O
the	O
exploratory	O
nature	O
of	O
the	O
initial	O
phase	O
of	O
the	O
clinical	O
study	O
.	O

Subgroup	O
and	O
sensitivity	O
analyses	O
for	O
patients	O
intubated	O
at	O
or	O
within	O
six	O
hours	O
after	O
randomization	O
was	O
performed	O
.	O

